Implantica's RefluxStop™ featured in seven presentations accepted at the largest US GI conference, SAGES

Dr. Peter Forsell, CEO of Implantica, says, "It's a humbling distinction to have RefluxStop™ included in seven scientific research abstracts that will be presented at SAGES, the biggest GI surgeon meeting in the US. It speaks volumes about the rapidly growing interest from top surgeons in RefluxStop™'s unique way of treating GERD. We're grateful these independent surgeons are committed to evaluating and reporting the impact that RefluxStop™ and surgical GERD treatment can have on patients." Dr...

Dr. Peter Forsell, CEO of Implantica, says, "It's a humbling distinction to have RefluxStop™ included in seven scientific research abstracts that will be presented at SAGES, the biggest GI surgeon meeting in the US. It speaks volumes about the rapidly growing interest from top surgeons in RefluxStop™'s unique way of treating GERD. We're grateful these independent surgeons are committed to evaluating and reporting the impact that RefluxStop™ and surgical GERD treatment can have on patients."

Dr. Forsell continues, "More than 1 billion people suffer from GERD worldwide, including as high as nearly 28%^[1] of the population in North America. Patients suffering from GERD condition deserve urgent attention from healthcare providers and policymakers. I'm excited for SAGES attendees to learn about RefluxStop™ treatment designed to bring a paradigm shift in how GERD is treated and potentially help millions of patients who struggle with this disease."

For further information, please contact:
Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, info@fnca.se

The information was sent for publication, through the agency of the contact person set out above, on February 1, 2024, at 08:00 a.m. (CET).

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energizing platform designed to power remote-controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

About RefluxStop™

RefluxStop™ is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. It's unique mechanism of action differentiates it from standard of care and current surgical solutions. 

Longer established surgical options for GERD involve encircling the food passageway to support the lower esophageal sphincter's closing mechanism and are commonly associated with side effects such as swallowing difficulties, pain when swallowing and inability to belch and/or vomit.

In contrast, the RefluxStop device treats the cause of acid reflux without encircling and putting pressure on the food passageway. It restores and maintains the lower esophageal sphincter in its original, natural position. The RefluxStop™ mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux.

Newsroom
https://www.implantica.com/media/media-kit

Community
https://ch.linkedin.com/company/implantica
https://www.twitter.com/implantica

Media Contact:
Implantica AG
Juanita Eberhart, VP Marketing & Advocacy
M: +1 925-381-4581
juanita.eberhart@implantica.com 

Reference:

1.  Yamasaki T., Hemond C., Mohamed E., Ganocy S., Fass R. The Changing Epidemiology of Gastroesophageal Reflux Disease: Are Patients Getting Younger? J Neurogastroenterol Motil. 2018 24(4):559-569.

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/implanticas-refluxstop-featured-in-seven-presentations-accepted-at-the-largest-us-gi-conference-sages-302050275.html